Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Barrier's Antifungal Drug Meets Phase IIb Endpoints | Contract Pharma

Barrier’s Antifungal Drug Meets Phase IIb Endpoints

Barrier Therapeutics achieved positive results from its Phase IIb dose ranging study for its antifungal candidate pramiconazole (previously known as Azoline). Pramiconazole met the primary endpoint of effectively treating tinea (pityriasis) versicolor, a common skin fungal infection characterized by a discolored, scaly, itchy rash primarily on the back, chest and upper arms. Also, the secondary endpoints of complete cure, mycological cure and investigators’ global assessment achieved statistical significance.

The randomized, double-blind, placebo-controlled study enrolled 147 patients in six treatment groups. Results showed a positive linear dose response for the primary endpoint “effectively treated” at day 28, which was defined as significant reduction in disease signs and symptoms, including redness, scaling and itching, and complete mycological cure. Response rates for the primary endpoint ranged from 35% for the lowest dose to 85% for the highest dose as compared to 16% for placebo. The drug was well tolerated across all treatment arms and no serious adverse events were reported.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters